NADAC vs. AWP Pricing
NADAC and AWP are both drug pricing benchmarks used across the U.S. healthcare system — but they measure fundamentally different things. NADAC reflects what pharmacies actually pay for drugs. AWP is a published list price with no required connection to real transaction data. The gap between them can be enormous, especially for generics.
NADAC
AWP
Side-by-Side Comparison
The core difference: NADAC is derived from real pharmacy invoices. AWP is a manufacturer-set list price with no standardized methodology and no audit.
| Dimension | NADAC | AWP |
|---|---|---|
| Full name | National Average Drug Acquisition Cost | Average Wholesale Price |
| Published by | CMS (Centers for Medicare & Medicaid Services) | Commercial compendia (Red Book, Medi-Span, First Databank) |
| Basis | Actual pharmacy invoice data from voluntary surveys | Manufacturer-reported list price — not tied to real transactions |
| What it represents | What pharmacies actually pay to acquire drugs from wholesalers | A published benchmark price; historically ~20% above WAC with no standard definition |
| Transparency | High — methodology is public, data is freely available from CMS | Low — proprietary, set by manufacturers, no audit requirement |
| Update cadence | Weekly (published every Monday) | Varies by compendia; typically monthly or when manufacturer updates |
| Level | NDC (11-digit) | NDC (11-digit) |
| Cost to access | Free (public CMS data) | Paid subscription (Red Book, Medi-Span) |
| Relationship to actual cost | Close — derived from real invoices, typically the most accurate public benchmark | Inflated — widely acknowledged as a "sticker price" that overstates true acquisition cost |
| Primary use | Medicaid reimbursement, PBM contract benchmarking, cost analysis | Legacy contract pricing, co-pay calculations, some commercial plan reimbursement |
The AWP–NADAC Spread
The gap between AWP and NADAC varies dramatically by drug type. For high-volume generics, AWP can be 15–30x the actual acquisition cost. For brand-name drugs, the spread is typically much narrower (1.1–1.3x). This spread is why AWP has been called “Ain't What's Paid” in the industry.
| Drug | NADAC / unit | AWP / unit | Spread |
|---|---|---|---|
| Atorvastatin 20 MG Oral Tablet (generic)High-volume generic — large spread typical | $0.05 | $0.82 | ~16x |
| Lisinopril 10 MG Oral Tablet (generic)Commodity generic — maximum AWP inflation | $0.02 | $0.55 | ~27x |
| Eliquis 5 MG Oral Tablet (brand)Brand drug — spread is narrower | $17.50 | $19.72 | ~1.1x |
| Humira 40 MG/0.8 ML Pen (brand)Specialty biologic — modest spread | $6,922 | $7,646 | ~1.1x |
Illustrative per-unit prices. Actual rates vary by NDC and date. NADAC is publicly available; AWP requires a compendia subscription.
Why the Difference Matters
Reimbursement accuracy
If a pharmacy is reimbursed at AWP minus a discount (e.g., AWP-15%), the actual margin depends entirely on how far AWP is from true acquisition cost. For generics, AWP-based reimbursement can produce enormous hidden margins. NADAC-based reimbursement aligns payments more closely to actual cost.
Contract benchmarking
PBM contracts frequently reference AWP as the pricing basis. Without a transparent benchmark like NADAC, it is difficult to evaluate whether "AWP-20%" represents a competitive rate or an inflated spread. Analysts increasingly use NADAC as a reality check on AWP-based contracts.
Formulary cost modeling
When modeling the cost impact of formulary changes, using AWP overstates the actual cost of generic alternatives. NADAC provides a more realistic basis for estimating what a utilization shift will actually cost.
State Medicaid programs
Most state Medicaid programs have moved to NADAC-based pharmacy reimbursement, replacing AWP-based formulas. CMS recommends NADAC as the preferred benchmark for federal upper limits (FUL) on generic drugs.
The Full Drug Pricing Landscape
NADAC and AWP are two benchmarks in a broader landscape. WAC, ASP, and MAC each serve different use cases in the drug pricing ecosystem.
| Benchmark | Source | Basis | Cadence |
|---|---|---|---|
| NADAC | CMS | Pharmacy invoice surveys | Weekly |
| AWP | Compendia | Manufacturer-set list price | Monthly |
| WAC | Manufacturer | List price to wholesalers | Varies |
| ASP | CMS | Net selling price after rebates | Quarterly |
| MAC | PBMs / States | PBM or state-set ceiling price | Varies |
How TwinFyRx handles drug pricing
TwinFyRx ingests NADAC weekly and Medicare ASP quarterly — both public, transparent benchmarks. All pricing data is keyed at the NDC level and joined to the RxNorm drug hierarchy via the ndc_rxnorm crosswalk, enabling pricing analysis at any level of the drug hierarchy from package to ingredient.